Nimbus Therapeutics

Executive Summary

Nimbus Therapeutics is a private biotechnology company headquartered in Cambridge, Massachusetts, that leverages computational chemistry and structural biology to design small-molecule inhibitors for well-validated yet challenging targets in oncology, immunology, and metabolic diseases. Founded in 2009, the company has raised over $335 million and employs between 50 and 200 people. Nimbus operates a unique 'hub-and-spoke' model, wherein it advances internal programs through early clinical development and then partners with major pharmaceutical companies for late-stage development and commercialization. This strategy has enabled efficient capital deployment and de-risking of its pipeline. The company's most advanced program is a TYK2 inhibitor for autoimmune diseases, which is partnered with AbbVie and currently in Phase 2 trials. Additional pipeline candidates include an HPK1 inhibitor for cancer immunotherapy and a novel allosteric inhibitor for metabolic disorders, both in early-stage clinical or preclinical development. Nimbus's platform-driven approach and strong partnerships position it to deliver breakthrough therapies across multiple therapeutic areas.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 data readout for NDI-101150 (TYK2 inhibitor) in psoriasis65% success
• Q2 2026Potential partnership or licensing deal for HPK1 program50% success
• Q3 2026IND filing for novel metabolic disease candidate70% success